ArticleNeoplasia (New York, N.Y.)2026
Tumor-specific super-enhancer drives overexpression of EVI1/MECOM in ovarian cancer.
Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (OC) is frequently diagnosed at an advanced stage, and despite surgery and chemotherapy, 70-80 % of patients relapse and die. Overcoming therapy resistance, e.g. by identifying molecular drivers, remains a major challenge. EVI1/MECOM, a known oncogene linked to poor prognosis in leukemia, is almost universally overexpressed in OC, suggesting a role in carcinogenesis. We report that aberrant EVI1/MECOM expression in OC is driven by a previously undiscovered 3' regulatory element. This ∼200 kb non-coding region downstream of EVI1/MECOM, is the most frequent recurrent chromosomal abnormality in OC. It interacts with the EVI1/MECOM promoter, shows high H3K27 acetylation and displays two 1.5 kb core regulatory elements, which are bound by the transcription factors SOX17 and PAX8, two markers routinely used to identify OC. Our findings reveal a novel enhancer-mediated mechanism of EVI1/MECOM overexpression in OC, offering insights into epigenetic regulation and potential therapeutic targets. TEASER: A novel mechanism of EVI1/MECOM dysregulation in Ovarian Cancer, revealing a potential vulnerability for therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.